This qualitative study of 37 HCPs in the UK has highlighted a lack of continuity in the prostate cancer care pathway between urologists and oncologists and the increased workload on oncologists posed by earlier introduction of newer systemic therapies presents new challenges in optimum care for men with prostate cancer. Furthermore, uncertainty exists around optimal selection, timing and sequencing of chemotherapy and second-line treatment amongst the HCPs.
The trials which assessed the use of abiraterone and enzalutamide for men with CRPC were predominantly in men with good PS (Eastern Cooperative Oncology Group, ECOG 0–1) [5, 8, 29,30,31]. For the minority of men in these trials with a poorer PS (ECOG ≥2) no significant OS benefit was demonstrated with either abiraterone or enzalutamide. For this reason NICE recommends the use of these drugs in men with CRPC with no or mild symptoms. In the post-docetaxel setting abiraterone is only recommended in men whose disease has progressed on or after one docetaxel-containing chemotherapy regimen. NICE recommends use of enzalutamide in a pre-docetaxel setting or post one course of docetaxel-containing regimen in men with no or mild symptoms (PS 0–1).
The recently published LATITUDE and STAMPEDE trial data has demonstrated an OS benefit and radiographic-progression free survival benefit of abiraterone and prednisolone alongside ADT in men in men with newly diagnosed, metastatic hormone sensitive prostate cancer and men initiating long term ADT [32, 33]. It is likely that abiraterone will therefore shift to earlier use in the prostate cancer pathway, similar to the shift seen with docetaxel. There may be further uncertainty surrounding optimum therapy sequencing, and neither study assessed the initiation of ADT plus abiraterone alongside docetaxel or versus ADT plus docetaxel, so there lacks comparative data for the new standard of care. Therefore for those with a poorer PS, the need for robust data around the efficacy of subsequent treatments after progression becomes crucial.
Docetaxel is a widely used drug, relatively inexpensive and a common therapy used for CRPC. Conceptually, the move to earlier administration in the care pathway men presenting with metastatic disease simultaneous with initiation of long term ADT following publication of the CHAARTED and STAMPEDE studies [9,10,11] has been relatively easy. Nevertheless, it is recognised that whilst the implementation of docetaxel earlier is both recommended and feasible, there are implications on the care pathway and resource utilisation [34] with additional workload for oncologists and increased demand on oncology units. Discontinuity between urology and oncology might risk delayed referral and compromise the treatment which can be offered to a man; treatment which he should be eligible for. As described by the medical oncologist (see “Stampede and Chaarted” Table 2) this has arguably risked sub-optimal care by restricting the numbers of men referred for chemotherapy.
Figures from the Royal College of Radiology report estimates that 67 full-time oncology consultants are required immediately to cover the current excess of clinical workload in the NHS and nearly 1 in 5 could retire from the workforce in the next 5 years [35]. With an ever-growing cancer population which is surviving longer yet a lack of oncology work force to meet the required demands on the cancer services, the NHS is facing a potential crisis [35].
In addition to the immediate strain brought on by the change in the prostate cancer care pathway, it is important to consider how the introduction of docetaxel earlier will affect subsequent treatment sequencing at CRPC stages (Fig. 1). There was a lack of clarity in how docetaxel and second generation anti-androgens, abiraterone and enzalutamide, may be sequenced for men in the post-STAMPEDE era. Including how decisions would be made to give further docetaxel chemotherapy regimens, if men have previously received docetaxel, and how effective a second docetaxel regimen may be further down the line. Some of the HCPs commented that second generation anti-androgens, would be offered in the place of chemotherapy where it is felt the man may not tolerate docetaxel due to a poorer PS.
With a lack of trial data, clinical guidance and clarity surrounding treatment sequencing, treating clinicians face a major dilemma. They may have to make a treatment evaluation on a patient and potentially offer unsuitable treatments based on the premise that there is no suitable alternative. Furthermore, the optimum pre- or post-docetaxel therapy is heavily debatable in CRPC given that there is no suitable comparison data, forcing clinicians to make decisions based on assumptions and clinical experience rather than true “level one” data.
Based on the findings from the interviews, some clinicians seem to be treating patients with poorer PS’ with abiraterone preferentially over chemotherapy whilst there lacks available data as to whether it may actually improve survival. Contraindications to docetaxel use are a poor PS (ECOG 3–4, caution for those with PS 2) [36]. This gives such men even fewer treatment options, given that NICE does not recommend the use of second generation anti-androgens. With these limitations, we can conclude that fitness is a key aspect in treatment decision making by clinicians and improving or maintaining a man’s PS to 0–1 enables access to the necessary therapies and ensures the best possible outcomes.
Fitness for treatment is a predominant factor in a clinician’s treatment based decision [37] and in advanced cancer populations remains a significant barrier for access to the available therapies in patients with a poor PS. Physiological adverse-effects of ADT such as fatigue, muscle wasting and increased central adiposity, which can significantly impact on QoL, can also compromise eligibility for treatment, where it interferes with performance status.
The shift in treatment paradigms to move docetaxel earlier in the care pathway comprises of both positive effects and a degree of uncertainty when fitness for treatment is considered. On one hand, men receiving docetaxel at hormone sensitive stages will likely be on average younger and have a better PS when compared to the castrate resistant setting. The combination of docetaxel with ADT at hormone sensitive stages has also been shown to significantly increase progression free survival meaning these men enter the castrate resistant phase of the disease later [38]. These men are therefore, at this stage, not only likely to tolerate the docetaxel better, maintaining the optimum drug dosage, but prolong the time to which they will need further therapy for advancing disease. On the other hand, when men do eventually progress to CRPC, the long term effects of a previous docetaxel regimen on PS and fitness for treatment are unclear. This may also be compounded by the adverse-effects of long term ADT given that these men can remain on first line ADT for many years.
Treatment evaluation of a patient with CRPC is pertinent given the predominance of muscle wasting and deterioration in bone health [39]. The effects of muscle wastage appear to have significant implications on the fitness and PS of a man, and therefore not only impacting his current therapy but also likely to affect the future treatments offered as his disease progresses. Retrospective data has associated better OS in men with metastatic prostate cancer receiving docetaxel with increased lean body mass [20].
The findings highlighted a lack of clarity over the origin of the muscle wastage and subsequently how it may be assessed and treated, where generally the HCPs spoke of a subjective assessment “by eye”. Given that a side-effect of ADT includes central and visceral obesity; such subjective assessments are likely to be misleading [40]. This poses a significant risk specific to these men where long term ADT is likely to mask any underlying muscle wasting pathology. Equally, symptoms of muscle wastage are very generalizable and can be difficult to distinguish from that of other treatment-related side effects (e.g. fatigue, impaired immune function and metabolic abnormalities) [39]. Research must focus on accurate and objective diagnostic measures of muscle wastage to enable its successful treatment, improving both the physiological wellbeing of these men and subsequently their response to cancer therapies.
There was an overwhelming view amongst HCPs that currently very little is offered in the way of treatment to address muscle wastage. Generally, diet and exercise advice was offered for a majority of muscle wastage seen in the clinic. Success from this approach was viewed as variable and may be in part due to a lack of consistency from HCP to HCP in the subjective nature of general “exercise and diet advice” and the “one size fits all” approach.
Compromising treatment was also mentioned by some of the HCPs. Cessation of ADT or restricting the use of steroids may be the case for men where muscle wastage is of a significant detriment to QoL at the potential cost of a survival benefit.
The consensus amongst the HCPs was that exercise presents as an effective therapy, improving both physiological and psychological outcomes as well as a tool aiding in the management of adverse-effects. Almost all the HCPs seemed to have knowledge of the current NICE recommendations however there was some confusion as to why action had not been taken nationally to implement them.
As described earlier, it is clear that maintaining or improving the PS of a man through his prostate cancer journey is critical to obtaining the best possible outcomes. This includes the potential alleviation of adverse-effects of treatment and the maintenance of a good QoL, where the two go hand in hand. There is increasing evidence demonstrating that exercise may represent a useful stand alone or combination therapy for the treatment of cancer, improving physiological and psychosocial outcomes [41]. In addition, specific beneficial effects of exercise training for improving lean body mass (LBM) are also well established [24, 42].
By improving physical fitness through exercise there is potential to not only improving the chances of receiving, but also better tolerating, the appropriate cancer treatments. Studies investigating the effectiveness of resistance and aerobic training in cancer populations have demonstrated an increase in chemotherapy completion rate and treatment toxicities [42,43,44].
Most of the HCPs felt that exercise should form a fundamental part of healthcare throughout the prostate cancer care pathway. Support should be offered from the beginning of a patient’s journey with prostate cancer and carried right to the end even where he may reach the castrate resistant phase of the disease, although there is a significant lack of data for such interventions in the population.
It is important to acknowledge the limitations to this study. This qualitative study did not seek to establish generalizability of findings but sought to gain a deeper insight into the views and opinions of a selected group of HCPs regarding the prostate cancer care pathway. The study has highlighted some critical issues facing prostate cancer treatment and management within the NHS. However it is acknowledged that testing these findings among a wider population of HCPs would be is warranted in order to test the generalizability of the findings. As the majority of interviewees were urologists and oncologists the data may be more biased to the perspectives of this particular group of professionals. Due to the nature of how these participants were recruited into the study the authors acknowledge that a self-selection bias may also exist as 63% (n = 49) of the HCPs approached expressed an interest in the research themes; the sampling of the participants in this study failed to address the views of those who did not express an interest. The thematic framework approach to analysing the data were used, although commonly used in healthcare research; this form of analysis is more inductive and therefore stays strongly informed by a priori reasoning [45].
To our knowledge, this is the first qualitative study of HCPs to have focused on second-line treatment sequencing; changes to practice due to the STAMPEDE and CHAARTED trial data; adverse-effects of prostate cancer treatment including muscle wastage, compromising treatment and finally prostate cancer and exercise, with a focus to men with CRPC. This study has highlighted the need to investigate further with a wider group of HCPs as well as involving the views, opinions and experiences of men with CRPC. Further observations are needed to develop clarity in the current prostate cancer care pathway, identifying weaknesses as we evolve and refine how we treat prostate cancer. Efforts need to be made to help expand the oncology workforce as the demand for cancer care is ever increasing. This will help enable clinicians to carry out consistent care but also recognise the need to vary treatment regimens dependant on a patient’s individual needs. This is particularly the case for those with CRPC who may have remained on ADT for a number of years and therefore experience significant detrimental adverse-effects from treatment including muscle wastage. In addition, this study has highlighted a lack suitable exercise provision based on the NICE recommendations. Future research should focus on how this can be improved and particularly in men with more advanced disease who have a higher disease burden, where the current data for exercise in this population lacks.